PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
35.35
-0.02 (-0.06%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close35.37
Open35.38
Bid35.01 x 900
Ask35.92 x 1100
Day's Range35.26 - 35.45
52 Week Range30.51 - 36.78
Volume11,817,430
Avg. Volume16,327,338
Market Cap210.71B
Beta1.07
PE Ratio (TTM)25.86
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (3.62%)
Ex-Dividend Date2017-11-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters24 minutes ago

    Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

    Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday. The National Health Service spent 34 million pounds on liothyronine tablets last year, up from 600,000 pounds a decade ago, after Concordia increased the price per pack by almost 6,000 percent from 4.46 pounds to 258.19 pounds. CMA Chief Executive Andrea Coscelli said: "Pharmaceutical companies which abuse their position and overcharge for drugs are forcing the NHS - and the UK taxpayer - to pay over the odds for important medical treatments.

  • Reuters26 minutes ago

    Drug firm Concordia overcharged Britain's health service with 6,000 pct price rise

    Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday. The National Health Service spent 34 million pounds ($45 million) on liothyronine tablets last year, up from 600,000 pounds a decade ago, after Concordia increased the price per pack by almost 6,000 percent from 4.46 pounds to 258.19 pounds. CMA Chief Executive Andrea Coscelli said: "Pharmaceutical companies which abuse their position and overcharge for drugs are forcing the NHS - and the UK taxpayer - to pay over the odds for important medical treatments.

  • Reuters1 hour ago

    Britain says Canada's Concordia overcharging health service for thyroid drug

    Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday. The National Health Service spent 34 million pounds ($45 million) on liothyronine tablets last year, up from 600,000 pounds a decade ago, after Concordia increased the price per pack by almost 6,000 percent from 4.46 pounds to 258.19 pounds. CMA Chief Executive Andrea Coscelli said: "Pharmaceutical companies which abuse their position and overcharge for drugs are forcing the NHS - and the UK taxpayer - to pay over the odds for important medical treatments.

  • Capital Cube17 hours ago

    ETFs with exposure to Pfizer Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfizer Inc. Here are 5 ETFs with the largest exposure to PFE-US. Comparing the performance and risk of Pfizer Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Tax reform could come before 2018, so a strategist says buy these 2 stocks
    CNBC3 days ago

    Tax reform could come before 2018, so a strategist says buy these 2 stocks

    According to one strategist, there will be two clear winners of the current GOP tax plan.

  • Associated Press3 days ago

    Nevada refusing Pfizer demand for return of execution drugs

    A Nevada prisons official said Friday the state is refusing pharmaceutical company Pfizer's demand to return a drug it manufactured and not use it in a planned lethal injection execution.

  • Nevada wants to use untried execution drugs that pose risks
    Associated Press3 days ago

    Nevada wants to use untried execution drugs that pose risks

    LAS VEGAS (AP) — For Nevada's first execution in more than a decade, state officials are turning to a never-before-tried combination of drugs, including a powerful painkiller that is fueling much of the nation's opioid epidemic and a paralyzing drug that could mask any signs of trouble.

  • Associated Press3 days ago

    The Latest: Nevada won't return execution drug to Pfizer

    The Latest on a pharmaceutical company's demand that states not use drugs it made for lethal injection executions (all times local): 5:30 p.m. An official says Nevada doesn't plan to return one of the ...

  • Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion
    Zacks4 days ago

    Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

    Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

  • Market Realist4 days ago

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold."

  • InvestorPlace4 days ago

    Why It’s Time to Put Pfizer Inc. Stock on Your Watchlist

    Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. Early this week, Purkiss made a point of saying sales of Ibrance is being underestimated, suggesting that rather than achieving just a little less than $7 billion in revenue in 2023, it could actually produce nearly $13-billion worth of business that year as its approved uses were expanded and caregivers saw its efficacy.

  • Trump may eliminate health provision in tax bill
    Yahoo Finance Video18 hours ago

    Trump may eliminate health provision in tax bill

    Republicans are willing to do just about anything to push tax reform through Congress. Even if that means dropping the repeal of the Affordable Care Act mandate, which requires that most people have health insurance or pay a penalty. Yahoo Finance’s Alexis Christoforous and Myles Udland figure the next move the GOP may take.

  • Stay away from big pharma?
    CNBC Videos13 hours ago

    Stay away from big pharma?

    Carter Worth, Cornerstone Macro, discusses what stocks to avoid in the pharmaceuticals sector. The “Fast Money” traders weigh in.